Love the episode? Send us a text! Inside the VIKTORIA-1 trial with Dr. Rachel LaymanWhat the New Genitolasib Data Mean for ER+ / HER2- Metastatic Breast Cancer In this episode of Breast Cancer Conversations, Laura sits down with Dr. Rachel Layman, breast medical oncologist at MD Anderson Cancer Center, to unpack what’s new in ER-positive, HER2-negative metastatic breast cancer—and why clinical trials are not just a last-ditch option. Dr. Layman walks us through the VIKTORIA-1 trial, a phase I...
All content for Breast Cancer Conversations is the property of SurvivingBreastCancer.org and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Love the episode? Send us a text! Inside the VIKTORIA-1 trial with Dr. Rachel LaymanWhat the New Genitolasib Data Mean for ER+ / HER2- Metastatic Breast Cancer In this episode of Breast Cancer Conversations, Laura sits down with Dr. Rachel Layman, breast medical oncologist at MD Anderson Cancer Center, to unpack what’s new in ER-positive, HER2-negative metastatic breast cancer—and why clinical trials are not just a last-ditch option. Dr. Layman walks us through the VIKTORIA-1 trial, a phase I...
259. 23andMe Found my BRCA Mutation with Debbie Lesser
Breast Cancer Conversations
36 minutes
6 months ago
259. 23andMe Found my BRCA Mutation with Debbie Lesser
Love the episode? Send us a text! Genetic tests like 23andMe are perceived as a fun and engaging way to explore family history, However, the implications of genetic testing extend beyond mere curiosity about ancestry; they touch on the very fabric of our lives and the lives of our loved ones. For those who discover they carry genes associated with increased cancer risk, like Lesser, the stakes are high. It raises questions about proactive measures, such as screenings or preventive surge...
Breast Cancer Conversations
Love the episode? Send us a text! Inside the VIKTORIA-1 trial with Dr. Rachel LaymanWhat the New Genitolasib Data Mean for ER+ / HER2- Metastatic Breast Cancer In this episode of Breast Cancer Conversations, Laura sits down with Dr. Rachel Layman, breast medical oncologist at MD Anderson Cancer Center, to unpack what’s new in ER-positive, HER2-negative metastatic breast cancer—and why clinical trials are not just a last-ditch option. Dr. Layman walks us through the VIKTORIA-1 trial, a phase I...
